Free Trial

Dogwood Therapeutics Q1 2023 Earnings Report

Dogwood Therapeutics logo
$4.25 +0.07 (+1.67%)
As of 04/4/2025 04:00 PM Eastern

Dogwood Therapeutics EPS Results

Actual EPS
-$2.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Dogwood Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Dogwood Therapeutics Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Remove Ads

Dogwood Therapeutics Earnings Headlines

Dogwood regains Nasdaq compliance
Dogwood Therapeutics, Inc. Regains Nasdaq Compliance
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Dogwood doses first patient in Phase 2b trial of Halneuron
See More Dogwood Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dogwood Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dogwood Therapeutics and other key companies, straight to your email.

About Dogwood Therapeutics

Dogwood Therapeutics (NASDAQ:DWTX) is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

View Dogwood Therapeutics Profile

More Earnings Resources from MarketBeat